Management of multiple myeloma (MM) has evolved considerably in recent years with the introduction of novel therapies and the multiple combinations of treatment options used in various stages of MM treatment. In this activity, experts will discuss the latest evidence on current and emerging therapies in MM to inform the selection and sequencing of multiple lines of therapy based on patient-, disease- and treatment-related factors. Don’t miss this opportunity to hear best practices for individualizing therapy and multidisciplinary MM care collaboration in federal, public, and government healthcare settings.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/elevating-treatment-selection-sequencing-multiple-myeloma-personalized
- Start Date: 2024-10-11 05:00:00
- End Date: 2024-10-11 05:00:00
- Credit Details: IPCE Credits: 1.25 hours
AAPA Category 1 Credit™️: 1.25 hours
AMA PRA Category 1 Credit™️: 1.25 hours
Nursing: 1.25 hours
Pharmacy: 1.25 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 6250.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 9375.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 7437.5 - Is Kind Support: False Source: Sobi - Amount: 5000.0 - Is Kind Support: False Source: Taiho Oncology, Inc - Amount: 12437.5 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest